eVAFBL was significantly higher in patients with liver metastases (median eVAF 2.92% vs 0.32%, p = 0.02) but was not associated with other clinicopathological or genomic covariates in our cohort (e.g., bone-only disease, history of primary endocrine resistance, contemporality of archival tissue for panel generation, PI3K pathway alterations, DNA damage repair alterations, TMB) (Supplementary Fig. 2a). Here, PIK3CA is linked to glycogen storage disease VI.